A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease

IF 2.2 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2024-12-06 DOI:10.1111/ajd.14391

Malindi Georgia Haggett MBBS(Hons), BMedSci(Hons), MSc, MPP(Dist), Sangho Lee BMedSci, MD, Francis Yi Xing Lai MBBS(Hons), FACD

{"title":"A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease","authors":"Malindi Georgia Haggett MBBS(Hons), BMedSci(Hons), MSc, MPP(Dist), Sangho Lee BMedSci, MD, Francis Yi Xing Lai MBBS(Hons), FACD","doi":"10.1111/ajd.14391","DOIUrl":null,"url":null,"abstract":"<p>This study systematically reviews existing data on the efficacy of Tyrosine Kinase 2 (TYK2) inhibitors in comparison to placebo or standard treatments for therapeutic benefit and improving quality of life in dermatological diseases. Seventeen records representing 13 clinical trials, one matching-adjusted indirect comparison, and one case study were included. Results indicate that Deucravacitinib is superior to placebo, Apremilast and Adalimumab in treating adult patients with moderate-to-severe plaque psoriasis and superior to placebo in the treatment of adults with systemic lupus erythematosus. Comparative investigations on Brepocitinib and Ropsacitinib were more limited. Oral Brepocitinib demonstrated superiority over placebo in managing alopecia areata, and hidradenitis suppurativa. Topical Brepocitinib exhibited superiority over placebo in treating atopic dermatitis, but not plaque psoriasis. Ropsacitinib demonstrated superiority over placebo in the management of plaque psoriasis. Brepocitinib and Ropsacitinib had more side effects than Deucravacitinib.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 1","pages":"1-13"},"PeriodicalIF":2.2000,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajd.14391","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This study systematically reviews existing data on the efficacy of Tyrosine Kinase 2 (TYK2) inhibitors in comparison to placebo or standard treatments for therapeutic benefit and improving quality of life in dermatological diseases. Seventeen records representing 13 clinical trials, one matching-adjusted indirect comparison, and one case study were included. Results indicate that Deucravacitinib is superior to placebo, Apremilast and Adalimumab in treating adult patients with moderate-to-severe plaque psoriasis and superior to placebo in the treatment of adults with systemic lupus erythematosus. Comparative investigations on Brepocitinib and Ropsacitinib were more limited. Oral Brepocitinib demonstrated superiority over placebo in managing alopecia areata, and hidradenitis suppurativa. Topical Brepocitinib exhibited superiority over placebo in treating atopic dermatitis, but not plaque psoriasis. Ropsacitinib demonstrated superiority over placebo in the management of plaque psoriasis. Brepocitinib and Ropsacitinib had more side effects than Deucravacitinib.

查看原文本刊更多论文

TYK2抑制剂对皮肤病患者疗效的系统评价

本研究系统地回顾了酪氨酸激酶2 （TYK2）抑制剂与安慰剂或标准治疗相比在治疗效果和改善皮肤病生活质量方面的有效性的现有数据。包括17条记录，代表13项临床试验，1项匹配调整的间接比较和1项病例研究。结果表明，Deucravacitinib在治疗中度至重度斑块型银屑病成人患者方面优于安慰剂、阿普拉米司特和阿达木单抗，在治疗系统性红斑狼疮成人患者方面优于安慰剂。brepositinib和Ropsacitinib的对比研究较为有限。口服布雷西替尼在治疗斑秃和化脓性汗腺炎方面优于安慰剂。局部布雷西替尼在治疗特应性皮炎方面优于安慰剂，但在治疗斑块性银屑病方面优于安慰剂。罗帕西替尼在治疗斑块型银屑病方面优于安慰剂。brepositinib和Ropsacitinib的副作用大于Deucravacitinib。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.